NAD+

DOCUMENT / REVISION	SDS-BBL-NAD-PLUS / D2
PREPARED	13 October 2026 | Replaces D1; catalog details rechecked
CATALOG PRESENTATION	1000 mg vial | Lyophilized powder
REVIEW STATUS	Buffered NAD+ identified in supplied COA; buffer composition and concentrations required.

Product-specific preparation document. Blank evidence is not a finding of safety. No hazard rating or regulatory compliance certification is asserted.

01 Identification

PRODUCT IDENTIFIER	NAD+ | nad-plus
RECOMMENDED USE	Laboratory research only. Not for human or veterinary use.
RESPONSIBLE PARTY	Blackwell BioLabs / Blackwell Biosciences LLC - legal entity, U.S. address and telephone pending confirmation.
EMERGENCY CONTACT	Not supplied. Responsible party must confirm an appropriate emergency contact before release.

02 Hazard identification

CLASSIFICATION	Pending assessment of exact supplied material. Do not infer non-hazardous status.
LABEL ELEMENTS	Signal word, statements, pictograms and precautions: not assigned.
OTHER HAZARDS	Review incomplete. NFPA / HMIS ratings not assigned.
UNKNOWN TOXICITY	Mixture status and applicable unknown-toxicity percentage require composition review.

03 Composition / ingredient information

IDENTITY / IDENTIFIERS	Catalog trade name: NAD+. Chemical identity, CAS and salt/counterion require supplier confirmation.
INGREDIENTS	Full composition and concentrations not supplied. Include buffers, preservatives, excipients and relevant impurities.
FORMULATION BASIS	Chromatographic purity does not establish total formulation mass fraction.

04 First-aid measures

EXPOSURE ROUTES	Inhalation, skin, eyes and ingestion: validated product-specific measures pending.
SYMPTOMS / TREATMENT	Acute/delayed effects and special-treatment requirements: not established. This draft is not an emergency guide.

05 Fire-fighting measures

MEDIA / HAZARDS	Suitable and unsuitable extinguishing media; hazardous combustion products: assessment pending.
RESPONDER PROTECTION	Product-specific protective equipment and precautions: pending.

06 Accidental release measures

PRECAUTIONS	Personnel, environmental and emergency precautions: pending formulation assessment.
CONTAINMENT / CLEANUP	Methods and cleanup materials require validation for the supplied lyophilized powder.

07 Handling and storage

SAFE HANDLING	Product-specific safe handling and incompatibilities: pending supplier evidence.
STORAGE	Catalog directs users to container conditions and expiry. Exact safety-storage range and restrictions remain unverified.

08 Exposure controls / personal protection

EXPOSURE LIMITS	Ingredient-specific PEL/TLV or other limits have not been assessed; no assertion that none exist.
CONTROLS / PPE	Engineering controls, eye/skin protection and respiratory requirements: task-specific review pending.

09 Physical and chemical properties

CATALOG PHYSICAL FORM	Lyophilized powder (catalog assertion; reconcile with final supplied material).
APPEARANCE / ODOR	Color, odor and odor threshold: not established.
THERMAL / FIRE DATA	Melting/freezing, boiling range, flash point, flammability, explosive limits, ignition and decomposition temperatures: not established.
OTHER PROPERTIES	pH, viscosity, solubility, partition coefficient, vapor pressure, density, vapor density and particle characteristics: not established.

10 Stability and reactivity

STABILITY / REACTIONS	Not established for the supplied formulation; supplier evidence and review pending.
CONDITIONS / MATERIALS	Conditions to avoid, incompatible materials and decomposition products: not established.

11 Toxicological information

EXPOSURE / EFFECTS	Routes, symptoms, acute and chronic effects, interactions and numerical toxicity measures: assessment pending.
CARCINOGEN REVIEW	Current relevant listings and ingredient applicability have not been assessed.
DATA BASIS	No product-specific hazard assessment supplied. Testing purity or microbial growth does not establish human safety.

12 Ecological information

ENVIRONMENTAL DATA	Ecotoxicity, persistence, degradation, bioaccumulation, mobility and other effects: not assessed.

13 Disposal considerations

WASTE / PACKAGING	Waste characterization and applicable disposal requirements pending. Drain or ordinary-trash suitability is not established.

14 Transport information

TRANSPORT STATUS	Not determined. No non-dangerous-goods declaration is made.
CLASSIFICATION FIELDS	UN number, shipping name, class, packing group, environmental hazards, bulk transport and special precautions: pending.

15 Regulatory information

REGULATORY REVIEW	Product/formulation-specific applicability pending. This document does not establish OSHA/GHS compliance or clinical authorization.

16 Other information

SOURCES	Blackwell live catalog reviewed 13 Oct 2026; internal product verification record. See completion guide for evidence requirements.
DOCUMENT BASIS	16-section preparation structure informed by OSHA 29 CFR 1910.1200 Appendix D. No laboratory results or signatures reproduced.
RELEASE REQUIREMENT	Confirm formulation, supplier evidence, hazard assessment and contacts; obtain responsible-party approval before issuing.